51,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

The dysregulated activity of genetic regulatory networks contributes to neoplastic transformation by promoting aberrant expression of genes involved in regulating cell homeostasis. Therefore, characterization of regulatory networks in human cancer cells is a critical objective in understanding the molecular mechanisms of cell transformation. Modern high throughput technologies are providing the first window into regulatory processes on the genome scale, foretelling the ability of computational inference algorithms to produce models of regulatory networks that will revolutionize our…mehr

Produktbeschreibung
The dysregulated activity of genetic regulatory
networks contributes
to neoplastic transformation by promoting aberrant
expression of
genes involved in regulating cell homeostasis.
Therefore,
characterization of regulatory networks in human
cancer cells is a
critical objective in understanding the molecular
mechanisms of cell
transformation. Modern high throughput technologies
are providing
the first window into regulatory processes on the
genome scale,
foretelling the ability of computational inference
algorithms to
produce models of regulatory networks that will
revolutionize our
understanding and treatment of cancer by 1)
describing how
genomic alterations cause functional disruptions in
the network
regulating cell homeostasis, leading to aberrant cell
growth and
cancer, and 2) predicting therapeutic interventions,
in which critical
components of the network can be targeted to revert
the cancer
phenotype. This book will develop methods that
advance the current
state of the art in inferring genetic regulatory
networks from high
throughput data, with specific application to both
gene expression
and ChIP-on-chip data.
Autorenporträt
Dr. Margolin's work on gene regulatory networks has produced
numerous discoveries
on oncogenic mechanisms and therapeutic targets in hematopoietic
cancers. Currently
at the Broad Institute of Harvard and MIT, Dr. Margolin works on
building predictive
models for personalized medicine on the basis of molecularly
defined tumor subtypes.